» news
» hERG
» hERG
» hERG
» hERG
» hERG
» hERG
» hERG
» hERG
» hERG
Company Milestones

2018: We have installed one new analysis station to ramp up screening throughput and shorten study slots of our sponsors. The high level of automation implemented guarantees operational precision and speed.

2017: We are pleased to disclose our 1st catalogue version including plus 60 in vitro ion channel assays for drug screening. Successful launch of cardiac APD evaluation using hIPSC derived cardiomyocytes.

2013: For consolidation of core resources Anaxon AG has moved to the capital city of Switzerland. New laboratories and offices have been equipped and furnished in the former company building of Dr. Meyer AG.

2012: Anaxon AG is a spin-off company of the Channelopathy Foundation and by 12-07-2012 has been registered as a Swiss non-stock corporation. The company has acquired the complete DNA/Cell asset package from former Genionics AG.